Rapid Acute Myeloid Leukemia (AML) Panel

AML Diagnostics: Beating the 7-Day Induction Window with Next-Day Results

Bridge the gap between clinical urgency, ICC, WHO, and NCCN-compliant and CEBPA targeted therapy.

  • The Cost of Waiting: Don’t treat in the dark or delay therapy while waiting for a reference lab. Even “rapid” NGS labs can take up to 7 days, while the critical AML induction treatment window closes at Day 7
  • NCCN-Compliant Speed: Get actionable results for FLT3, IDH1, IDH2, KIT, & NPM1, and CEBPA the next day, ensuring your patient starts the correct targeted inhibitor from Day 1
  • 100% NGS Concordance: Match the quality and precision of standard NGS testing, delivered at the speed of qPCR
  • Zero-CAPEX Integration: Run the panel on your existing qPCR hardware (QuantStudio 3, 5, 7 & 12). Retain the Technical Component (TC) revenue without a $300k+ equipment investment
  • The Hybrid Advantage: Start by sending samples to our CAP/CLIA lab to stabilize your workflow. When you’re ready, transition the testing to your own bench with Precipio as your permanent clinical backup
Technical Overview IFU SDS Shop

Rapid AML Panel Pre-Plated Plate Layout

AML Panel Plate Layout

The BloodHound® Rapid AML Panel offerings are research use only assays that detect somatic mutations in targets of interest related to Acute Myeloid Leukemia (AML). This panel is specifically designed to detect mutations using High Resolution Melt Analysis in FLT3, KIT, IDH1, IDH2, and NPM1 genes. This reagent set is designed to be used by suitably trained personnel testing DNA extracted from whole blood or bone marrow samples.

Development Of The BloodHound® Rapid AML Panel

Precipio’s own clinical hematopathology laboratory developed the BloodHound® Rapid AML panel to address the issues of turn-around time and accurate, comprehensive molecular testing for gene mutations associated with acute myeloid leukemia (AML). By taking a panel approach to gene mutation detection for suspected acute myeloid leukemias, Precipio’s clinical hematopathology lab is able to rapidly identify these gene mutations in a single assay run on one platform. This provides our lab with a more efficient testing workflow and enables rapid turn around time on this acute condition to empower clinicians with critical data to inform targeted treatment decisions.

BloodHound® Rapid Acute Myeloid Leukemia (AML) Assay Configurations

The BloodHound® Rapid AML panel comes pre-plated with optimized primers and embedded mutant, NTC, and wild type controls for driver mutation genes of interest in AML. This simplifies lab inventory management by providing a complete molecular assay without tracking multiple SKUs of single gene testing assays that require separate control kits. This also provides a rapid solution for the lab to deliver timely answers.

Single sample pre-plated, and vialed free flow configurations are available for the AML panel. Custom configurations are also possible for all or individual genes.

BloodHound® Workflow

DNA Workflow

Sample preparation follows standard DNA extraction techniques. Most HRM-enabled RT-PCR instruments can run the Bloodhound® Rapid AML assay after DNA samples are plated. Data is captured in real time, and melt curves can be analyzed to determine the mutation status of FLT3, KIT, IDH1, IDH2, and NPM1 genes.

Publications related to the BloodHound® Rapid AML Panel